You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

FGFR3 gene activation

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Solid Tumor Trial (TYRA-300)

Not yet recruiting
  • Locally Advanced Urothelial Carcinoma
  • +3 more
  • (no location specified)
Sep 15, 2022

Iron, Alpha-Synuclein, and Lymphocyte-activation Gene-3 in

Not yet recruiting
  • Brain Ischemia
  • Serum Iron
  • +7 more
  • Aswan, Egypt
    Aswan University Hospital
Mar 7, 2023

Solid Tumor, Adult, Intrahepatic Cholangiocarcinoma, Urothelial Carcinoma Trial in Taiwan, United States (KIN-3248)

Recruiting
  • Solid Tumor, Adult
  • +2 more
  • La Jolla, California
  • +4 more
Aug 9, 2022

FGFR1 Gene Amplification, FGFR1 Gene Mutation, FGFR1 Gene Translocation Trial in United States (Pemigatinib, Quality-of-Life

Active, not recruiting
  • FGFR1 Gene Amplification
  • +18 more
  • Scottsdale, Arizona
  • +5 more
Oct 18, 2022

Urinary Bladder Tumors, Tumor Metastasis, Ureteral Tumors Trial in New York, Myrtle Beach, Nashville (LOXO-435, Pembrolizumab)

Recruiting
  • Urinary Bladder Neoplasms
  • +2 more
  • New York, New York
  • +2 more
Jan 31, 2023

Bladder Cancer, Recurrent Bladder Cancer, FGFR3 Gene Mutation Trial in United States (Erdafitinib)

Recruiting
  • Bladder Cancer
  • +2 more
  • Basking Ridge, New Jersey
  • +6 more
Aug 22, 2022

Advanced Malignant Solid Tumor, Cholangiocarcinoma, Metastatic Malignant Solid Tumor Trial in Columbus (Infigratinib)

Recruiting
  • Advanced Malignant Solid Neoplasm
  • +3 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Feb 15, 2022

Recurrent Glioblastoma, IDH-Wildtype, Recurrent WHO Grade 2 Glioma, Recurrent WHO Grade 3 Glioma Trial (Biospecimen Collection,

Not yet recruiting
  • Recurrent Glioblastoma, IDH-Wildtype
  • +2 more
  • Biospecimen Collection
  • +2 more
  • (no location specified)
May 13, 2023

Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib

Recruiting
  • Bladder Cancer
  • +12 more
  • Raleigh, North Carolina
    xCures Virtual Site
Sep 20, 2021

Cholangiocarcinoma, FGFR2 Fusion, FGFR2 Gene Mutation Trial in United States (TT-00420)

Recruiting
  • Cholangiocarcinoma
  • +4 more
  • Anchorage, Alaska
  • +16 more
Jan 3, 2023

Cholangiocarcinoma,Adult Trial (3D185)

Not yet recruiting
  • Cholangiocarcinoma,Adult
  • (no location specified)
Sep 2, 2021

Circulating Tumor DNA-Guided Late-Line Treatment in Late-Stage

Completed
  • Metastatic Breast Cancer
  • +2 more
  • Control group
  • Case group
  • (no location specified)
Jun 16, 2022

Urothelial Carcinoma Trial in Shanghai (AZD4547)

Recruiting
  • Urothelial Carcinoma
  • Shanghai, Shanghai, China
    Fudan University Cancer Hospital
Oct 20, 2021

Cholangiocarcinoma Trial in China, Japan (E7090)

Active, not recruiting
  • Cholangiocarcinoma
  • Bengbu, Anhui, China
  • +55 more
Jan 24, 2023

Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma AJCC v6 and v7, Stage III Bladder Urothelial

Not yet recruiting
  • Muscle Invasive Bladder Urothelial Carcinoma
  • +3 more
  • Biospecimen Collection
  • +7 more
  • (no location specified)
Aug 10, 2023

Cancer, Cancer Metastatic, NTRK Gene Fusion Overexpression Trial in Worldwide (Data collection and quality of life

Recruiting
  • Cancer
  • +15 more
  • Data collection and quality of life questionnaire
  • Graz, Austria
  • +40 more
Jul 27, 2021

Advanced Cholangiocarcinoma, FGFR2 Gene Rearrangements Trial in Worldwide (TAS-120, Cisplatin/Gemcitabine)

Active, not recruiting
  • Advanced Cholangiocarcinoma
  • FGFR2 Gene Rearrangements
  • Albuquerque, New Mexico
  • +100 more
Feb 1, 2023

Advanced Cholangiocarcinoma, FGFR2 Gene Mutation Trial in Worldwide (BGJ398, Gemcitabine, Cisplatin)

Active, not recruiting
  • Advanced Cholangiocarcinoma
  • FGFR2 Gene Mutation
  • Gilbert, Arizona
  • +115 more
Oct 17, 2022

Nasopharyngeal Carcinoma Trial (procedure, drug, biological)

Not yet recruiting
  • Nasopharyngeal Carcinoma
  • Biospecimen Collection
  • +9 more
  • (no location specified)
Sep 12, 2023

On Craniosynostosis, Skull Malformations With Premature Fusion

Recruiting
  • Craniosynostosis
  • Craniosynostosis Network Environmental Survey
  • +6 more
  • Davis, California
  • +19 more
Jul 5, 2022

TIA, Carotid Artery Plaque, Carotid Atherosclerosis Trial in Cambridge (Interleukin-2 [IL-2], Standard care - Carotid

Not yet recruiting
  • TIA
  • +2 more
  • Interleukin-2 [IL-2]
  • Standard care - Carotid Endarterectomy
  • Cambridge, Cambridgeshire, United Kingdom
    Addenbrookes Hospital
Aug 2, 2023

NSCLC With Mutation in Epidermal Growth Factor Receptor Trial in Kunming (Combined therapy of anlotinib and aumolertinib)

Recruiting
  • Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
  • Combined therapy of anlotinib and aumolertinib
  • Kunming, Yunnan, China
    First Affiliated Hospital of Kunming University
Oct 22, 2023

Cutaneous Melanoma, Mucosal Melanoma, Ocular Melanoma Trial in New York, Houston (biological, other, procedure)

Active, not recruiting
  • Cutaneous Melanoma
  • +10 more
  • Ipilimumab
  • +4 more
  • New York, New York
  • +1 more
Aug 25, 2021

Solid Tumours Trial in Worldwide (Debio1347 (CH5183284))

Terminated
  • Solid Tumours
  • Debio1347 (CH5183284)
  • Boston, Massachusetts
  • +7 more
Sep 8, 2020

Locally Advanced NSCLC, Efficacy and Safety Trial in Guangzhou (Anlotinib, Chemotherapy, Radiotherapy)

Recruiting
  • Locally Advanced Non-small Cell Lung Cancer
  • Efficacy and Safety
  • Guangzhou, Guangdong, China
    Sun yat-sen University Cancer Center
Jul 28, 2022